Proof of concept studies for tissue-protective agents in multiple sclerosis

Multiple Sclerosis

Volumn 15, Issue 5, 2009, Pages 542-546

  Mehta, Lahar R ^a   Schwid, S R ^a   Arnold, D L ^b   Cutter, G R ^c   Aradhye, S ^d   Balcer, L J ^d   Calabresi, P A ^e   Cohen, J A ^f   Cole, P E ^g   Glanzman, R ^d   Goelz, S ^g   Inglese, M ^g   Kapoor, R ^h   Kappos, L ⁱ   Kreitman, R ^j   Lublin, F D ^k   Mann, A ^g   Marrie, R A ^l   O'Looney, P ^m   Polman, C H ⁿ   Ravina, B M ⁿ   Reingold, S C ^o   Richert, J R ^m   Sandrock, A W ^g   Waubant, E ^p   more..

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g NEW YORK UNIVERSITY   (United States)

^h NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^j TEVA PHARMACEUTICALS   (Israel)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF MANITOBA   (Canada)

^m National Multiple Sclerosis Society   (United States)

ⁿ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^o Scientific and Clinical Review Associates LLC   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Clinical trial designs; Multiple sclerosis; Outcome measurement; Tissue protection

Indexed keywords

CORTICOSTEROID; GLATIRAMER; NATALIZUMAB; NEUROPROTECTIVE AGENT; PLACEBO;

BRAIN ATROPHY; BRAIN SIZE; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DRUG RESPONSE; HUMAN; MULTIPLE SCLEROSIS; NEUROPROTECTION; OPTIC NEURITIS; REVIEW;

HUMANS; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 65349186498     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508101939     Document Type: Review

References (15)

1. Karussis D. Grigoriadis S Polyzoidou E Grigoriadis N Slavin S Abramsky O. Neuroprotection in multiple sclerosis. Clin Neurol Neurosurg 2006; 108: 250-254.
2. McFarland HF Reingold SC. The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic era. Mult Scler 2005; 11: 669-676.
3. Rudick RA. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis. J Neuroimaging 2004; 14: 54S-64S.
4. Hardmeier M Wagenpfeil S Freitag P. European IFN-B1a in Relapsing MS Dose Comparison Trial Study Group. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology 2005; 64: 236-240.
5. Hardmeier M Wagenpfeil S Freitag P. Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis. Arch Neurol 2003; 60: 1736-1739.
6. Gordon-Lipkin E Chodkowski B Reich DS. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 2007; 69: 1603-1609.
7. Balcer LJ Baier ML Cohen JA. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology 2003; 61: 1367-1373.
8. Baier ML Cutter GR Rudick RA. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology 2005; 64: 992-995.
9. Balcer LJ Galetta SL Calabresi PA. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 2007; 68: 1299-1304.
10. Anderson VM Bartlett JW Fox NC Fisniku L Miller DH. Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates. J Neurol 2007; 254: 1588-1594.
11. Rudick RA Fisher E Lee JC Simon J Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53: 1698-1704.
12. Lublin FD Baier M Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61: 1528-1532.
13. Weinshenker BG O'Brien PC Petterson TM. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878-886.
14. Filippi M Rovaris M Rocca MA. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 2001; 57: 731-733.
15. Dalton CM Miszkiel KA Barker GJ. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004; 251: 407-413.